Opioid deaths in the United States have fallen to their lowest level in nearly a decade, according to new figures announced by the U.S. Department of Health and Human Services (HHS) on October 27, 2026. The department says opioid-related deaths are now at their lowest since President Donald Trump first declared the opioid crisis a public health emergency in 2017 — a milestone that, if the provisional numbers hold, would mark a genuine turning point in a crisis that has claimed more than a million American lives since the turn of the century.
HHS Secretary Robert F. Kennedy Jr. announced the findings at an event at the Detroit Wayne Integrated Health Network in Detroit, Michigan, alongside a new analysis from the department’s Office of the Assistant Secretary for Planning and Evaluation (ASPE) and an article in Health Affairs Forefront. The announcement pairs two related but distinct findings: a record-low overall death rate for the country in 2025, and a decade-long shift in how opioids are prescribed and treated.
“President Trump has attacked the opioid crisis from every direction — rightsizing opioid prescribing, disrupting the fentanyl supply chain, and expanding treatment and recovery,” Kennedy said. “Those actions are saving lives and driving opioid deaths to the lowest in nearly a decade. We will keep pressing forward until every American struggling with addiction has a real path to recovery and a chance to rebuild a healthy life.”
What the new numbers actually show
The ASPE report, titled “The U.S. Age-Adjusted Death Rate Reached a Record Low in 2025: What Drove the Decline?”, examines provisional data from the Centers for Disease Control and Prevention (CDC) showing that America’s overall age-adjusted death rate reached 689.2 deaths per 100,000 people in 2025 — the lowest ever reported. That figure covers deaths from all causes, not opioids alone, and it provides the backdrop against which the opioid-specific progress is measured.
The opioid-specific picture comes from pharmacy dispensing data tracked from March 2015 through March 2026. Adjusted for population, researchers found a dramatic reshaping of America’s relationship with prescription opioids over that decade: opioid prescriptions dispensed fell to 45.3 percent of their March 2015 level; total opioid dosage dispensed fell even further, to 35.2 percent of the baseline; the number of patients receiving prescription opioids through retail pharmacies fell to 49.6 percent of the baseline. At the same time, the number of patients filling retail prescriptions for buprenorphine or naltrexone — medications used to treat substance use disorders — rose to 218 percent of the baseline.
In plain terms: far fewer Americans are starting or staying on prescription opioids, the doses being dispensed are much smaller, and more than twice as many people are getting medicines that help treat addiction rather than feed it. HHS presents that combination — less prescribing, more treatment — as the core of the improvement.
The CDC’s wider overdose data tells the same story from a different angle. Provisional CDC figures put total U.S. drug overdose deaths at an estimated 69,973 in 2025, down almost 14 percent from 81,313 in 2024. Deaths involving opioids fell to an estimated 44,564 in 2025, from 55,296 a year earlier — a drop of roughly one-fifth, and the third consecutive annual decline. Almost every state saw decreases, with Rhode Island, New York, North Carolina, Alabama and Vermont recording declines of 25 percent or more.
Why officials say opioid deaths are falling
HHS credits a two-term policy effort that began in Trump’s first presidency and was renewed after his return to office in 2025. In 2018, Trump signed the SUPPORT for Patients and Communities Act, strengthening federal prevention, treatment and recovery programmes. His administration also set out to cut nationwide opioid prescription fills by one-third within three years, and in 2018 the Justice Department and the Drug Enforcement Administration (DEA) proposed lowering 2019 manufacturing quotas for six frequently misused opioids by an average of 10 percent. HHS says those policies led to the first reduction in drug-related deaths in nearly three decades.
Since 2025, the administration says it has renewed that agenda on several fronts at once. Trump signed the SUPPORT for Patients and Communities Reauthorization Act of 2025, continuing and updating programmes for substance use disorders, overdose prevention and recovery. The DEA intensified efforts to disrupt the global fentanyl supply chain and launched its Fentanyl Free America initiative. The administration also points to the closure of the southern border to illegal crossings as part of cutting fentanyl supply routes. In January 2026, Trump established the Great American Recovery initiative to better align federal programmes and integrate prevention, treatment, recovery support and reentry across government systems.
“For families living with addiction, saving a life means another birthday, another holiday together, another chance to come home — that is what President Trump’s commitment to this fight is about,” said HHS Senior Advisor Kathryn Burgum, co-chair of the Great American Recovery. “Through the President’s Great American Recovery, we will keep our focus on the people behind the numbers and the families counting on the Trump Administration to save more American lives.”
Experts outside government have offered additional explanations for the decline that go beyond any single administration’s policies. The wide availability of naloxone, the overdose-reversing medicine, is widely credited with saving lives on the spot. Expanded addiction treatment, shifts in how people use drugs, and billions of dollars in opioid lawsuit settlement money flowing into state and local programmes have all been cited. Some researchers also note that fewer teenagers are taking up drugs, and that the population most at risk has tragically shrunk as many long-term users have died.
Why the good news comes with warnings
For all the progress, nobody involved in the data is declaring the crisis over — and the numbers themselves explain why. An estimated 44,564 opioid deaths in a single year is still a staggering toll, roughly equivalent to losing a mid-sized American town every year. Synthetic opioids, including fentanyl, remain the single largest contributor to overdose deaths in the country, according to the CDC.
The figures are also provisional, meaning they are incomplete and subject to revision as more death records are submitted to the National Vital Statistics System. Toxicology backlogs, inconsistent reporting standards between states and deaths misclassified under other causes have historically meant the real total sits somewhat above the first official estimate.
Progress has also been uneven. While most states saw large declines, New Mexico, Arizona and Colorado recorded increases of 10 percent or more in drug overdose deaths in 2025 compared with 2024, according to the CDC. That unevenness is a reminder that national averages can hide local crises still getting worse.
There is a further risk that researchers and advocates have warned about before: when headlines declare a crisis is improving, funding and attention can drift away just when treatment programmes need sustained support. The history of the opioid epidemic — which began with prescription painkillers in the 1990s, moved through heroin, and then exploded with illicit fentanyl — shows how quickly a drug crisis can change shape. Deaths peaked at nearly 110,000 in 2022 before falling in 2023, dropping sharply in 2024 and falling again in 2025. Holding that decline will depend, experts say, on keeping naloxone widely available, treatment easy to reach and fentanyl supply routes disrupted at the same time.
What to watch next
The next test of the HHS announcement will be whether final, rather than provisional, CDC data confirm the 2025 decline, and whether the downward trend continues into 2026. The ASPE report and the Health Affairs Forefront analysis will also face scrutiny from independent researchers, who will want to separate how much of the improvement comes from prescribing changes, how much from treatment expansion and how much from enforcement against fentanyl trafficking.
For families, the practical message in the new data is simpler and more immediate. Treatment with buprenorphine or naltrexone is now far more common than it was a decade ago, naloxone is widely available and can reverse an opioid overdose in minutes, and the national decline — uneven and incomplete as it is — means thousands of people who might otherwise have died in 2025 are still alive. That, HHS argues, is what the lowest opioid death rate in nearly a decade actually means: not the end of the crisis, but the first sustained sign that it can be turned around.
Source: U.S. Department of Health and Human Services, “Trump Administration Drives Opioid Deaths to Lowest in Nearly a Decade,” October 27, 2026; CDC National Center for Health Statistics provisional overdose data for 2025.